Pharma Asia 2026: ‘Life expectancy in Pakistan has improved by 10 years between 1999 and 2026’
KARACHI: The life expectancy in Pakistan has increased by approximately 10 years over the past 27 years, a speaker claimed at the Pharma Asia 2026 conference, partly attributing the betterment in lives to improved access to and use of medicines by patients in the country between 1999 and 2026. “Pakistan’s average life expectancy has improved by 10 years from 1999 to 2026 due to medication,”…
At the Pharma Asia 2026 conference, Hamid Raza, CEO of Neutro Pharma, stated that the average life expectancy in Pakistan has increased by 10 years from 1999 to 2026 due to better access to and use of medicines. According to World Bank data, the average life expectancy in Pakistan rose to 67.8 years in 2024 from 59.7 years in 1990, a growth of 8.1 years over 34 years.
Dr. Faisal Khokhar, Senior Vice Chairman of the Pakistan Pharmaceutical Manufacturers Association (PPMA), expressed optimism about the country's pharmaceutical sector, predicting that a third pharmaceutical company is expected to achieve Stringent Regulatory Authority (SRA) status next year, potentially allowing for the export of locally produced medicines to high-value international markets such as the US, UK, EU, Japan, Canada, and Australia.
Khokhar emphasized the importance of international accreditation for attracting private equity and venture capital investments into the pharmaceutical sector, which is highly capital-intensive. The PPMA Chairman, Adnan Hirani, highlighted the participation of over 800 pharmaceutical players and 200 foreign delegates at the 24th Pharma Asia and 14th International Pharma Convention, with a focus on attracting technology, innovation, and investment from local and global firms.
Written by urgent.news from Business Recorder's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
